Anti-CD20 mABs are human immunoglobulin G1 and high-affinity antibodies that target a novel epitope on CD20 on the B-cell membrane. Monoclonal antibodies designed to target CD20 are used in various medical applications, particularly in the treatment of certain autoimmune diseases and hematological malignancies, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Product

7 Market Segmentation by Application

8 Customer Landscape

9 Geographic Landscape